TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22965594

Group type: EXPERIMENTAL
Intervention: Angle closure (PACS, PAC, PACG)
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Shallower ACD
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Shorter AL
Number of subjects: 1426
Study: 22965964

Group type: EXPERIMENTAL
Intervention: SB1518 (100 to 600 mg/d)
Number of subjects: 34
Study: 22966090

Group type: EXPERIMENTAL
Intervention: Children with type 1 diabetes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study: 22966170

Group type: EXPERIMENTAL
Intervention: Short alleles (≤ 25 repeats) of HMOX1 gene promoter polymorphism
Number of subjects: 942

Group type: COMPARATOR
Intervention: Longer alleles of HMOX1 gene promoter polymorphism
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: HMOX1 gene promoter polymorphism
Number of subjects: 942
Study: 22966847

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment protocols
Number of subjects: 0
Study: 22967195

Group type: EXPERIMENTAL
Intervention: Point-of-purchase (POP) nutrition information intervention
Number of subjects: 224
Study: 22967868

Group type: EXPERIMENTAL
Intervention: Topical 1.0% bevacizumab for 3 weeks
Number of subjects: 20
Study: 22967996

Group type: EXPERIMENTAL
Intervention: Neratinib (240 mg) plus vinorelbine (25 mg/m2)
Number of subjects: 79
Study: 22968145

Group type: EXPERIMENTAL
Intervention: SD-OCT analysis in AMD eyes
Number of subjects: 467

Group type: COMPARATOR
Intervention: Control group (no AMD)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Foveal drusen associated with other foveal pathology
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Focal hyperreflectivity over drusen
Number of subjects: 467
Study: 22968466

Group type: EXPERIMENTAL
Intervention: Hub vascular neurologists using ResolutionMD
Number of subjects: 53
Study: 22968742

Group type: EXPERIMENTAL
Intervention: COR-1 (10-240 mg, single i.v. administration)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (matching placebo, single i.v. administration)
Number of subjects: 50
Study: 22969103

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 22969149

Group type: EXPERIMENTAL
Intervention: pH1N1 vaccine (revaccination)
Number of subjects: 40

Group type: COMPARATOR
Intervention: pH1N1 vaccine (initial vaccination)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control HCWs (no revaccination)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: pH1N1 vaccine (for LRs)
Number of subjects: 40
Study: 22970121

Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D in patients with TnT release
Number of subjects: 982

Group type: COMPARATOR
Intervention: Lowest quartile of 25(OH)D
Number of subjects: 982
Study: 22970753

Group type: EXPERIMENTAL
Intervention: Adherence to preventive care recommendations
Number of subjects: 4931

Group type: EXPERIMENTAL
Intervention: Smoking cessation advice
Number of subjects: 4931

Group type: EXPERIMENTAL
Intervention: Referral to smoking cessation program
Number of subjects: 4931

Group type: EXPERIMENTAL
Intervention: Hemoglobin-A1c screenings for diabetes
Number of subjects: 4931

Group type: EXPERIMENTAL
Intervention: Albumin excretion test for kidney disease
Number of subjects: 4931

Group type: EXPERIMENTAL
Intervention: Adherence rates for coronary artery disease, hypertension, and dyslipidemia
Number of subjects: 4931

Group type: EXPERIMENTAL
Intervention: Patients at target for blood pressure
Number of subjects: 4931

Group type: EXPERIMENTAL
Intervention: Patients at target for LDL-cholesterol levels
Number of subjects: 4931

Group type: EXPERIMENTAL
Intervention: Patients with diabetes at target for hemoglobin-A1c
Number of subjects: 4931
Study: 22971786

Group type: EXPERIMENTAL
Intervention: Daniel Fast with krill oil supplementation (2 g/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Daniel Fast with placebo supplementation (coconut oil; 2 g/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Daniel Fast (combined data from both groups)
Number of subjects: 39
Study: 22971949

Group type: EXPERIMENTAL
Intervention: OFDI with sampling rate of 0.125 mm
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: OFDI with sampling rate of 1.0 mm
Number of subjects: 126
Study: 22972437

Group type: EXPERIMENTAL
Intervention: EQ-5D (US weights)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HUI2 (Canadian weights)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HUI3 (Canadian weights)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Correlation between instruments
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Utility scores by depression severity
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Comparison to general US population
Number of subjects: 118
Study: 22972589

Group type: EXPERIMENTAL
Intervention: Selumetinib-based combination therapy (with dacarbazine, docetaxel, temsirolimus, or erlotinib)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Selumetinib-based combination therapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Selumetinib-containing regimens
Number of subjects: 18
Study: 22973678

Group type: EXPERIMENTAL
Intervention: Performance improvement intervention
Number of subjects: 7605

Group type: COMPARATOR
Intervention: Baseline use of B-blockers and aldosterone antagonists
Number of subjects: 7605

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists and HF education
Number of subjects: 7605
Study: 22973876

Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha (activated) (DAA) at 50 ng/ml and 5 μg/ml
Number of subjects: 104

Group type: COMPARATOR
Intervention: TNF alpha stimulation
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: DAA treatment
Number of subjects: 104
Study: 22974533

Group type: EXPERIMENTAL
Intervention: (18)F-FMISO dPET-CT and functional MRI combined with intensity modulated radiation therapy (IMRT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (18)F-FMISO dPET-CT and functional MRI
Number of subjects: 15
Study: 22974830

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 0
Study: 22975218

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study: 22977195

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² on day 1 and then 250 mg/m² weekly) in combination with docetaxel (75 mg/m² every 3 weeks or 35 mg/m² on days 1, 8, 15 every 4 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 38
Study: 22978540

Group type: EXPERIMENTAL
Intervention: Craniocervical decompression surgery
Number of subjects: 48
Study: 22978748

Group type: EXPERIMENTAL
Intervention: Vortioxetine (2.5, 5, 10 mg/day)
Number of subjects: 535
Study: 22980297

Group type: EXPERIMENTAL
Intervention: Gene Expression Score (GES)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Myocardial Perfusion Imaging (MPI)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Chest pain symptoms
Number of subjects: 1160
Study: 22980441

Group type: EXPERIMENTAL
Intervention: (177)Lu-cG250
Number of subjects: 23
Study: 22980667

Group type: EXPERIMENTAL
Intervention: Intracavitary video-assisted thoracoscopic surgery ultrasonography (VATS-US)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard VATS techniques
Number of subjects: 46
Study: 22981498

Group type: EXPERIMENTAL
Intervention: Panobinostat (20mg) three times every week
Number of subjects: 139
Study: 22981532

Group type: EXPERIMENTAL
Intervention: Barriers identified by nurses
Number of subjects: 138
Study: 22981957

Group type: EXPERIMENTAL
Intervention: Targeted health education or counseling
Number of subjects: 0
Study: 22982655

Group type: EXPERIMENTAL
Intervention: Radical local treatment (surgery or radiotherapy)
Number of subjects: 40
Study: 22983573

Group type: EXPERIMENTAL
Intervention: High hemolytic component quartile
Number of subjects: 415

Group type: COMPARATOR
Intervention: Hydroxyurea therapy
Number of subjects: 415

Group type: COMPARATOR
Intervention: Higher hemoglobin F
Number of subjects: 415

Group type: COMPARATOR
Intervention: Alpha-thalassemia
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Higher systemic pulse pressure, lower oxygen saturation, greater values for tricuspid regurgitation velocity, left ventricular diastolic dimension and left ventricular mass
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: High hemolytic component
Number of subjects: 415
Study: 22983583

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, lenalidomide and dexamethasone
Number of subjects: 21
Study: 22983877

Group type: EXPERIMENTAL
Intervention: New York University Caregiver Intervention (NYUCI) with case management by a community health worker (CHW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case management by a community health worker (CHW)
Number of subjects: 0
Study: 22984218

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg daily; 4 weeks on, 2 weeks off)
Number of subjects: 34
Study: 22985379

Group type: EXPERIMENTAL
Intervention: 50 mg riluzole twice daily for 28 doses, starting at a mean of 8.7 ± 2.2 hours postinjury.
Number of subjects: 35
Study: 22985381

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22987312

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (IM, 400 mg daily)
Number of subjects: 30
Study: 22987562

Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS) without nerve exposure during intraoperative neuromonitoring (IONM)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conventional method of VNS with nerve exposure
Number of subjects: 220
Study: 22989031

Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP < 1028 ng/L
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP in patients with concomitant procedure
Number of subjects: 383
Study: 22989869

Group type: EXPERIMENTAL
Intervention: Quality of life scores (measured by RAND36 dimensions: physical functioning and general health)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: BNP levels
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables
Number of subjects: 661
Study: 22990093

Group type: EXPERIMENTAL
Intervention: Classic CAH treatment regimen
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Nonclassic CAH treatment regimen
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Adult CAH patients
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Classic CAH females
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Nonclassic CAH females
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Classic CAH males
Number of subjects: 244
Study: 22990096

Group type: EXPERIMENTAL
Intervention: 25(OH)D below 20 ng/ml
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Low concentrations of 24,25-dihydroxyvitamin D
Number of subjects: 1193

Group type: COMPARATOR
Intervention: 25(OH)D of at least 30 ng/ml
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Circulating vitamin D metabolites
Number of subjects: 1193
Study: 22990174

Group type: EXPERIMENTAL
Intervention: Sterile human acellular dermal matrix
Number of subjects: 65
Study: 22990272

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047
Study: 22990319

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.3 or 0.5 mg)
Number of subjects: 19
Study: 22990455

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation with lung protective strategies
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Standard ventilatory settings at 24 hours post-assessment
Number of subjects: 146
Study: 22991217

Group type: EXPERIMENTAL
Intervention: Multicomponent interactive intervention (web-based CME, performance feedback, quality improvement tools)
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1182
Study: 22992045

Group type: EXPERIMENTAL
Intervention: Influenza A H1N1/2009 vaccine
Number of subjects: 95
Study: 22992437

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (1010 CFU/day, Ecologic®Performance or OMNi-BiOTiC®POWER)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 23
Study: 22992566

Group type: EXPERIMENTAL
Intervention: Epitope-based synthetic peptide vaccine candidates containing residues 211-225 of VP1 formulated with Freund's adjuvant (CFA/IFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant EV71 subunit vaccine (VP1) expressed in E. coli and formulated with CFA/IFA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA plasmid containing VP1 gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VP1 expressed in Salmonella typhimurium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant EV71 virus-like particles (rVLP) produced from baculovirus formulated with CFA/IFA or alum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic peptides or recombinant EV71 subunit vaccines (rVP1 and rVLP) formulated in alum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formalin-inactivated (FI) EV71 virions formulated in alum
Number of subjects: 0
Study: 22993389

Group type: EXPERIMENTAL
Intervention: Dapsone (2.5 mg/kg once daily for 3 days)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 319

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (control group)
Number of subjects: 319
Study: 22994896

Group type: EXPERIMENTAL
Intervention: Inhaled anesthetics
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravenous anesthetics
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 22995059

Group type: EXPERIMENTAL
Intervention: Dietary intake as per American Heart Association and National Heart, Lung, and Blood Institute nutrition parameters
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Dietary recommendations for urban African Americans
Number of subjects: 361
Study: 22995650

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) in the refractory group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) in the naive group
Number of subjects: 45
Study: 22995726

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 422

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Prasugrel (postoperative within 5 days after withdrawal)
Number of subjects: 422
Study: 22995875

Group type: EXPERIMENTAL
Intervention: Invasive strategy (IS)
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Conservative strategy (CS)
Number of subjects: 1645
Study: 22995885

Group type: EXPERIMENTAL
Intervention: High frailty score group
Number of subjects: 159

Group type: COMPARATOR
Intervention: Lower frailty score group
Number of subjects: 159
Study: 22996144

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) for 72 hours before and at 3, 6, 9, 12, 24, and 36 months after transplantation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 23
Study: 22996616

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Quetiapine IR
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 186
Study: 22997219

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-γ release assays (IGRAs)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: IFN-γ-induced protein (IP)-10
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Consecutive use of TST, IGRA, and IP-10
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Using three tests (TST, IGRA, IP-10)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Single test use
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (156 children)
Number of subjects: 330
Study: 22998112

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Number of subjects: 130

Group type: COMPARATOR
Intervention: RAPIDLab® 1265 blood gas analyser (BGA)
Number of subjects: 130
Study: 22998355

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting coronary stent system (EECSS)
Number of subjects: 5054
Study: 22998907

Group type: EXPERIMENTAL
Intervention: Intravesical oportuzumab monatox (30 mg) - cohort 1 (6 weekly instillations)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravesical oportuzumab monatox (30 mg) - cohort 2 (12 weekly instillations)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravesical oportuzumab monatox (30 mg)
Number of subjects: 46
Study: 22999213

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - calcic nadroparin, administered daily for one month.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - single dose of calcium nadroparin, studied for 12 hours.
Number of subjects: 0
Study: 22999294

Group type: EXPERIMENTAL
Intervention: Fulvestrant 4 mg/kg via monthly intramuscular injections for 12 months
Number of subjects: 30
Study: 22999729

Group type: EXPERIMENTAL
Intervention: Central to peripheral pulse pressure amplification (PPA)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: High blood pressure (BP)
Number of subjects: 1126
Study: 23000321

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23000649

Group type: EXPERIMENTAL
Intervention: Topical thalidomide gel
Number of subjects: 0
Study: 23001085

Group type: EXPERIMENTAL
Intervention: tacrolimus monotherapy with donor bone marrow cell infusion
Number of subjects: 5
Study: 23001257

Group type: EXPERIMENTAL
Intervention: Patients with Sjögren's syndrome (SS)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Positive ANA
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Positive RF
Number of subjects: 327
Study: 23001391

Group type: EXPERIMENTAL
Intervention: Bulimia Nervosa (BN)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: BN-type eating disorder not otherwise specified
Number of subjects: 76

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 76
Study: 23002195

Group type: EXPERIMENTAL
Intervention: Implantable cardiac defibrillator (ICD) therapy
Number of subjects: 235
Study: 23006321

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg bid
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fundoplication
Number of subjects: 69
Study: 23006802

Group type: EXPERIMENTAL
Intervention: E-MOSAIC software installed in handheld computer generating a longitudinal monitoring sheet (LoMoS) provided to oncologists
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care without LoMoS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: E-MOSAIC software
Number of subjects: 80
Study: 23007406

Group type: EXPERIMENTAL
Intervention: C allele at rs7142143 in the PYGL gene
Number of subjects: 2535

Group type: EXPERIMENTAL
Intervention: 134 SNPs associated with ALL relapse
Number of subjects: 2535

Group type: EXPERIMENTAL
Intervention: SNPs including variants in PDE4B and ABCB1
Number of subjects: 2535
Study: 23007746

Group type: EXPERIMENTAL
Intervention: MMF 4 g daily
Number of subjects: 30
Study: 23008465

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 500 U/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 1000 U/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 2500 U/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 24
Study: 23009127

Group type: EXPERIMENTAL
Intervention: Radioactive iodine remnant ablation
Number of subjects: 0
Study: 23009552

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch, mean maintenance dose 3.1 ± 1.1 mg/24 h
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 295
Study: 23009652

Group type: EXPERIMENTAL
Intervention: PHMB-based gynecological solution (Monogin®, Lo.Li. Pharma, Rome - Italy) for six months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 100
Study: 23010228

Group type: EXPERIMENTAL
Intervention: Puff City, a web-based, tailored asthma management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23010851

Group type: EXPERIMENTAL
Intervention: 500 mg oral dose of (14)C-dovitinib
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 400 mg daily nonlabeled dovitinib (continuous-dosing extension phase)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Adverse events related to dovitinib
Number of subjects: 13
Study: 23011914

Group type: EXPERIMENTAL
Intervention: Joint physical activity in residential locations (35%)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Joint physical activity in commercial venues (24%)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Joint physical activity in open spaces/parks (20%)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Joint physical activity comparison between obese and under/normal weight children and parents
Number of subjects: 291
Study: 23012326

Group type: EXPERIMENTAL
Intervention: r-hIL-7 (CYT107) administered weekly for 3 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 23013426

Group type: EXPERIMENTAL
Intervention: ACTS Burdens scale (12-item)
Number of subjects: 1336

Group type: EXPERIMENTAL
Intervention: ACTS Benefits scale (3-item)
Number of subjects: 1336
Study: 23014345

Group type: EXPERIMENTAL
Intervention: Low-dose IFN-γ pretreatment
Number of subjects: 12
Study: 23014524

Group type: EXPERIMENTAL
Intervention: CTC enumeration in 7.5 mL of blood
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: CTC concentration
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Flow cytometry for CTC detection
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: CTC frequency
Number of subjects: 836
Study: 23016889

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 700

Group type: COMPARATOR
Intervention: Untreated coeliac patients
Number of subjects: 700
Study: 23018280

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 or 15 mg/kg) every 3 weeks plus chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression.
Number of subjects: 215